CD274 and ovarian carcinoma: Our study is similar to the results of the JAVELIN solid tumor trial, showing that PD-L1 expression assays may not be able to fully predict patient response to immune-based chemotherapy, possibly due to the complex immune microenvironment of ovarian cancer itself.2